Evidence reviewed: 31 October 2026
Author: ExtolX Editorial Team
This is an educational overview of published research, not medical advice.
Retatrutide, also known as LY3437943, is an experimental peptide developed by Eli Lilly. It has attracted attention because one molecule is designed to activate three hormone-receptor systems connected with appetite, blood sugar and the way the body handles energy.
That three-part design is why retatrutide is often called a triple-receptor agonist. In ordinary language, it means the molecule is built to switch on three different biological message receivers.
The short version
- Retatrutide is designed to activate the GLP-1, GIP and glucagon receptors.
- These receptors influence fullness, blood-sugar control, digestion and energy use.
- Phase 2 trials produced encouraging results in obesity, type 2 diabetes and liver-fat research.
- By 31 October 2026, TRIUMPH-1, TRIUMPH-2 and sleep-apnoea findings had peer-reviewed reports. A further head-to-head result remained a company announcement.
- Retatrutide remains investigational and has not been approved by a medicines regulator.
On This Page
- The short version
- What is retatrutide?
- Why are researchers interested?
- What did the earlier human trials find?
- What has Phase 3 research added?
- What has research shown about tolerability?
- What do we still need to learn?
- What could the future hold?
- Plain-English glossary
- Explore Retatrutide research material
- References and further reading
What is retatrutide?
Hormones carry instructions around the body. A receptor is the part of a cell that receives one of those instructions. It works a little like a lock that responds to the right key.
Retatrutide is a single laboratory-designed molecule shaped to interact with three receptors:
GLP-1
GLP-1 is released after eating. Its signals help the body respond to food, support insulin release when blood sugar rises and contribute to feelings of fullness. It can also slow the speed at which food leaves the stomach.
GIP
GIP is another hormone released after food. It helps the pancreas respond to rising blood sugar. Researchers are interested in how GIP and GLP-1 signalling can work together.
Glucagon
Glucagon helps control how stored energy is made available. Its role is more complicated because it can raise blood sugar while also affecting fat processing and energy use. Retatrutide research explores whether carefully balancing this signal with GLP-1 and GIP can produce a useful overall metabolic effect.
The term GLP-3 is sometimes used online, but it is not a scientific hormone or an accurate name for retatrutide. “Triple-receptor agonist” is the correct description.
Why are researchers interested?
Earlier medicines in this area mainly focused on one receptor. Semaglutide, for example, acts through GLP-1. Tirzepatide acts through GLP-1 and GIP.
Retatrutide adds glucagon-receptor activity to those two signals. Researchers want to learn whether this can influence several parts of metabolism at once, including:
- Appetite and feelings of fullness
- Blood-sugar control
- Body-weight regulation
- How the body uses stored fat
- Fat held in and around the liver
- Wider measures such as blood pressure and blood fats
Its design is therefore important not only for the compound itself, but also for the future development of medicines that use several biological pathways together.
What did the earlier human trials find?
Phase 2 obesity research
A 48-week trial involved 338 adults with obesity or overweight. Average weight changes ranged from an 8.7% reduction in the lowest-dose group to 24.2% in the highest-dose group. The placebo group averaged a 2.1% reduction.
This was an important result, but Phase 2 trials are designed to explore whether an idea works well enough to justify larger testing. They are not the final stage of medicine development.
Type 2 diabetes research
Phase 2 work in adults with type 2 diabetes found changes in both blood-sugar measurements and body weight. In 2026, the peer-reviewed TRANSCEND-T2D-1 Phase 3 trial reported greater reductions in long-term blood sugar and body weight with retatrutide than with placebo over 40 weeks.
Liver-fat research
A smaller Phase 2 substudy used scans to measure liver fat in 98 participants. Large average reductions were reported in the higher-dose groups after 24 weeks. This was an encouraging signal, but it came from a relatively small substudy and used imaging rather than a direct tissue measurement.
What has Phase 3 research added?
Phase 3 research now includes published results in obesity, type 2 diabetes and sleep apnoea. It is important to separate those papers from company announcements and to keep each study population distinct.
Obesity without diabetes: TRIUMPH-1
The September 2026 TRIUMPH-1 paper reported an 80-week trial in 2,339 adults with obesity and no diabetes. Average body-weight reductions across its three retatrutide groups were 17.6%, 23.7% and 25.0%, compared with 3.9% in the placebo group. These are the paper’s main intention-to-treat figures, not the larger estimates in earlier company headlines.
Intention-to-treat means analysing people according to their original assigned group. The study’s analysis plan also specifies how to handle events such as stopping treatment and missing measurements. An estimate focused on continued treatment answers a different question. The two approaches should not be mixed or presented as interchangeable results.
Obesity with type 2 diabetes: TRIUMPH-2
The TRIUMPH-2 paper, published online in September 2026, tested a different population: 1,152 adults with type 2 diabetes and obesity or overweight. At 80 weeks, its treatment-regimen analysis reported average weight reductions of 11.9%, 16.8% and 18.8% across the retatrutide groups, versus 5.1% with placebo. Those results belong to this population and analysis; they should not be pooled with TRIUMPH-1 headline figures.
Sleep-apnoea research within those trials
An October 2026 peer-reviewed report examined participants with obstructive sleep apnoea, a condition in which breathing repeatedly stops or becomes restricted during sleep. These studies were nested within TRIUMPH-1 and TRIUMPH-2, not wholly separate populations. They found greater reductions than placebo in breathing interruptions per hour at 80 weeks. This adds condition-specific evidence, not proof of every longer-term outcome.
Other Phase 3 results and the newest comparison
TRANSCEND-T2D-1 already has a peer-reviewed report on blood sugar and body weight in type 2 diabetes. Earlier company announcements also covered TRIUMPH-3, in severe obesity with cardiovascular disease, and TRIUMPH-4, in obesity with knee osteoarthritis pain. Those announcements should not be treated as equivalent to the full journal papers described above.
On 28 October 2026, Lilly announced TRANSCEND-T2D-2 results, describing its sixth positive Phase 3 trial. The 80-week study directly compared retatrutide with a specified Ozempic formulation of semaglutide in adults with type 2 diabetes. Lilly reported greater reductions in long-term blood sugar and weight with retatrutide. At the 31 October 2026 review, this is company-reported topline evidence, not a peer-reviewed full report or a comparison with every semaglutide product.
Together, these studies expand the evidence base, but they do not establish regulatory approval or make independently supplied research material equivalent to the sponsor’s trial product.
What has research shown about tolerability?
The most common unwanted effects reported in trials have involved the digestive system, including nausea, diarrhoea, constipation and vomiting. These were often seen while doses were being increased. Some studies also reported altered skin sensation, described as tingling or unusual sensitivity.
Larger and longer studies are still needed to identify less common effects and understand what happens over several years rather than several months.
What do we still need to learn?
The new publications answer some questions, but important gaps remain:
- How well are changes maintained over the long term?
- What happens when treatment stops?
- How do the newest head-to-head results hold up in full publication, and what do direct comparisons show about longer-term outcomes?
- Which people are most likely to benefit, and which are more likely to experience unwanted effects?
- Will ongoing studies show improvements in major health outcomes rather than measurements such as weight alone?
- What will regulators conclude after reviewing the complete evidence package?
These questions are normal for a compound moving through late-stage development.
What could the future hold?
Retatrutide research now extends beyond body weight. Studies are investigating type 2 diabetes, sleep apnoea, knee osteoarthritis pain, liver disease, cardiovascular and kidney outcomes, and chronic lower-back pain.
Lilly stated in July 2026 that it planned to submit retatrutide for US regulatory review in the first quarter of 2027. A submission is not an approval, and decisions in the UK would follow their own process and timetable.
The wider scientific question is whether triple-receptor designs can provide useful effects across several connected metabolic conditions. Future results will show whether the early promise is matched by long-term benefits and an acceptable safety profile.
Plain-English glossary
- Agonist: A molecule that switches on a receptor.
- Receptor: A structure on or inside a cell that receives a biological message.
- Metabolism: The processes the body uses to turn food and stored fuel into energy.
- Placebo: An inactive comparison used to show whether changes are likely to be caused by the substance being tested.
- Phase 3 trial: A large, late-stage human study used to assess benefits and risks before a possible regulatory application.
- Intention-to-treat: Analysing participants by their original assigned group, using a stated plan for events such as treatment changes and missing data.
- Topline results: An initial summary of study findings, usually released before the full report can be examined.
Explore Retatrutide research material
ExtolX catalogues retatrutide research material in two separately listed amounts: Retatrutide 10mg and Retatrutide 20mg. Both pages describe the same stated peptide identity. They differ in the total amount supplied, SKU and batch documentation—not in the stated composition, purity or expected research performance.
Published clinical trials use Eli Lilly’s sponsor-manufactured investigational medicine. Independently supplied laboratory material is not the clinical-trial product and should not be treated as equivalent to it.
References and further reading
- Phase 2 obesity trial — New England Journal of Medicine
- Phase 3 type 2 diabetes trial — PubMed
- Phase 2 liver-fat trial — Nature Medicine
- TRIUMPH-1 Phase 3 results — Eli Lilly
- TRIUMPH-2 and TRIUMPH-3 topline results — Eli Lilly
- Retatrutide clinical-trial registry results — ClinicalTrials.gov
- TRIUMPH-1 peer-reviewed Phase 3 report — NEJM / PubMed, September 2026
- TRIUMPH-2 peer-reviewed Phase 3 report — The Lancet / PubMed, September 2026
- TRIUMPH-1-OSA and TRIUMPH-2-OSA report — NEJM / PubMed, October 2026
- TRANSCEND-T2D-2 company topline announcement — Eli Lilly, 28 October 2026
Research-use notice: ExtolX materials are supplied for laboratory research only and are not for human or veterinary use.